{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:16:52Z","timestamp":1783577812695,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B (CHB) is one of the most significant global public health issues because it is progressive and has long-term complications, with gaps in real-world management. Longitudinal cohort evidence is required to guide effective disease control strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the clinical burden, disease progression, and management strategies in patients with CHB and to identify factors influencing progression and treatment outcomes in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study design was a retrospective longitudinal cohort study conducted at a tertiary-care academic referral centre between January 2020 and December 2025. A total of 520 patients were analysed, all of whom were confirmed to have CHB and followed longitudinally through routine clinical care for a mean duration of 4.1\u202fyears. Assessment was made on clinical burden, disease progression and management strategies. Kaplan\u2013Meier analyses were used to determine progression-free survival, and multivariable Cox proportional hazards regression was used to determine independent predictors of disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>21.5% of patients in the baseline group were found to have significant fibrosis, and 9.8% of the patients had cirrhosis. Follow-up discovered disease evolution in 22.3%, including cirrhosis (11.9%), hepatocellular carcinoma (6.9%), and liver death (5.4%). 46.2% of the patients received antiviral therapy, which was associated with a high rate of progression-free survival. Older age, high levels of HBV DNA, baseline fibrosis, ALT elevation and diabetes mellitus were all independent predictors of disease progression, and antiviral therapy had a very strong protective effect (adjusted HR 0.52, 95% CI 0.36\u20130.75). It is important to note that almost 20% of eligible patients were not treated, and unstable monitoring was associated with poor clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CHB is associated with a significant clinical and healthcare burden. Antiviral interventions and regular observation in the early stages of the disease can greatly slow disease progression, and it is therefore crucial to enhance population health interventions to ensure a smooth transition between the guidelines applied and actual practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1790994","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:36:27Z","timestamp":1783575387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical burden, disease progression, and management strategies in chronic hepatitis B: implications for public health practice"],"prefix":"10.3389","volume":"14","author":[{"given":"Shuo","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Hepatology, Hepatology Research Institute, the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S2468-1253(25)00052-4","article-title":"Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines","volume":"10","author":"Cohen","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"23743735231211069","DOI":"10.1177\/23743735231211069","article-title":"The impact of living with chronic hepatitis B on quality of life: implications for clinical management","volume":"10","author":"Ibrahim","year":"2023","journal-title":"J Patient Exp"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.glmedi.2024.100058","article-title":"Advancing public health policies to combat hepatitis B in Africa: challenges, advances, and recommendations for meeting 2030 targets","volume":"2","author":"Faniyi","year":"2024","journal-title":"J Med Surg Public Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/ID9.0000000000000128","article-title":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (text extract): executive summary","volume":"4","year":"2024","journal-title":"Infect Dis Immun"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.gastha.2023.10.008","article-title":"The epidemiology, transmission, genotypes, replication, serologic and nucleic acid testing, immunotolerance, and reactivation of hepatitis B virus","volume":"3","author":"Patel","year":"2024","journal-title":"Gastro Hep Advances"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12985-020-01393-z","article-title":"Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study","volume":"17","author":"Zheng","year":"2020","journal-title":"Virol J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e70519","DOI":"10.1002\/jmv.70519","article-title":"Global disease and economic burden of noncommunicable diseases attributable to hepatitis B infection: a health economic evaluation study","volume":"97","author":"Wang","year":"2025","journal-title":"J Med Virol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5539\/gjhs.v17n1p63","article-title":"A systematic review study on lived experiences of people living with hepatitis B (PLHB)","volume":"17","author":"Adoboi","year":"2025","journal-title":"Glob J Health Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1565621","DOI":"10.3389\/fpubh.2025.1565621","article-title":"Prevalence and burden of HBV\u2013HIV co-morbidity: a global systematic review and meta-analysis","volume":"13","author":"Dagnaw","year":"2025","journal-title":"Front Public Health"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"100527","DOI":"10.1016\/j.clinme.2025.100527","article-title":"Chronic hepatitis B in 2025: diagnosis, treatment and future directions","volume":"25","author":"Watson","year":"2025","journal-title":"Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"049","DOI":"10.1055\/s-0039-3401031","article-title":"Role of biomarkers in guiding cure of viral hepatitis B","volume":"40","author":"Buti","year":"2020","journal-title":"Semin Liver Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s12072-024-10700-7","article-title":"Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C infection: a systematic review and meta-analysis","volume":"18","author":"Lv","year":"2024","journal-title":"Hepatol Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/MEG.0000000000001537","article-title":"Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom clinical practice research datalink","volume":"32","author":"Ferreira","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.jhep.2023.06.014","article-title":"Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year?","volume":"80","author":"Guan","year":"2024","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3350\/cmh.2020.0032","article-title":"Novel biomarkers for the management of chronic hepatitis B","volume":"26","author":"Inoue","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/diseases13100311","article-title":"Chronic hepatitis B: current management and future directions","volume":"13","author":"Ertugrul","year":"2025","journal-title":"Diseases"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/hbsn-2024-754","article-title":"2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges","volume":"14","author":"Yan","year":"2025","journal-title":"Hepatobiliary Surg Nut"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12985-025-02922-4","article-title":"Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis","volume":"22","author":"Duan","year":"2025","journal-title":"Virol J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1186\/s12889-024-20462-4","article-title":"Global, regional, and national total burden related to hepatitis B in children and adolescents from 1990 to 2021","volume":"24","author":"Li","year":"2024","journal-title":"BMC Public Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cld.2019.04.008","article-title":"WHO guidelines for prevention, care and treatment of individuals infected with HBV: a US perspective","volume":"23","author":"Vittal","year":"2019","journal-title":"Clin Liver Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14760584.2025.2502030","article-title":"Toward elimination of hepatitis a and B in Europe: vaccination successes, challenges, and opportunities","volume":"24","author":"Buti","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Statis. Soc."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1790994\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:36:28Z","timestamp":1783575388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1790994\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2026.1790994"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1790994","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1790994"}}